SUZHOU, China – A fitting end to an upbeat conference, the executive interview with Steve Yang, the newly anointed executive vice president and chief operating officer of Wuxi Pharmatech, left the crowd of entrepreneurs, scientists, executives and investors feeling optimistic about China's recent evolution and inspired to tackle the road ahead to bring China to a global level.
SHANGHAI – At the 6th DIA Annual Meeting here last week, many of the 1,500 attendees are justifiably concerned about how to get medicines into the hands of those who need it most in China faster and more efficiently, where drugs hit the market several years after the U.S. or EU.
SHANGHAI – Neostem Inc. (NASDAQ:NBS) has signed an exclusive license agreement with Cellular Biomedicine Group (OTCQB:CBMG), of Shanghai, for its patient-specific immunotherapy (DC-TC) to treat late-stage hepatocellular carcinoma (HCC) in China, home to more than 45 percent of the world's HCC patients.
SHANGHAI – In its third academic collaboration deal announced in China this year, Astrazeneca plc, of London, signed a translational research agreement with scientists from Tianjin Medical University (TMU) to explore novel targets for cardiac fibrosis, important in the area of cardiovascular disease (CVD).
SUZHOU, China – A fitting end to an upbeat conference, the executive interview with Steve Yang, the newly anointed executive vice president and chief operating officer of Wuxi Pharmatech, left the crowd of entrepreneurs, scientists, executives and investors feeling optimistic about China's recent evolution and inspired to tackle the road ahead to bring China to a global level.
SHANGHAI – In a press conference, the Ministry of Public Security (MPS) announced that its 10-month bribery investigation into the China operations of Glaxosmithkline plc had come to a close. The case will be transferred to provincial prosecutors in Changsha to further review the case.
SHANGHAI – At the 6th DIA Annual Meeting here this week, many of the 1,500 attendees are justifiably concerned about how to get medicines into the hands of those who need it most in China faster and more efficiently, where drugs hit the market several years after the U.S. or EU.
SHANGHAI – Aslan Pharmaceuticals Pte Ltd. signed an agreement for global rights with CSL Ltd. to develop an anti-IL-13 receptor monoclonal antibody, CSL334, for severe to moderate asthma.
SUZHOU, China – Navigating the obstacle course of China's regulatory system requires strategic thinking, long-term planning, creative problem solving and it doesn't hurt to have deep pockets, according to the experts discussing cross-border approvals at the Chinabio Partnering conference.
SHANGHAI – Aslan Pharmaceuticals Pte Ltd. signed an agreement for global rights with CSL Ltd. to develop an anti-IL13 receptor monoclonal antibody, CSL334, for severe to moderate asthma.
